• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Teva Pharmaceutical Industries ADR (NY: TEVA )

    14.05 UNCHANGED
    Streaming Delayed Price Updated: 7:00 PM EDT, Apr 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,009
    Open 14.05
    Bid (Size) 13.96 (2)
    Ask (Size) 13.99 (83)
    Prev. Close 14.05
    Today's Range 14.05 - 14.05
    52wk Range 7.085 - 14.46
    Shares Outstanding 1,110,352,397
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
    From Alvotech
    Via GlobeNewswire

    Performance

    YTD
    +31.68%
    +31.68%
    1 Month
    +1.01%
    +1.01%
    3 Month
    +19.78%
    +19.78%
    6 Month
    +63.75%
    +63.75%
    1 Year
    +58.94%
    +58.94%

    More News

    Read More
    US Supreme Court Declines To Hear Vanda Pharmaceuticals' Case Regarding Invalidation Of Patents For Its Sleep Disorder Drug, Hetlioz
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    8 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
    Via Benzinga
    Update: Israeli Stocks On U.S. Exchanges Have Outpaced Nasdaq And S&P 500 Since October 7/23
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
    From Alvotech
    Via GlobeNewswire
    Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Forget Nvidia: 3 Prominent Billionaire Investors Are Selling It and Buying These 6 Value Stocks Instead
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    3 No-Brainer Stocks to Buy With $600 Right Now
    Via The Motley Fool
    Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In'
    Via Benzinga
    Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month
    Via Benzinga
    The Generic Drugs Antitrust Case
    Via Talk Markets
    Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal
    Via Talk Markets
    Drug Maker Organon Stock Scores Relative Strength Upgrade
    Via Investor's Business Daily
    Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Ethereum Price Predictions: Where Will the ETH Crypto Go After Retaking $3,000?
    Via InvestorPlace
    Jefferies Just Raised Its Price Target on Salesforce (CRM) Stock
    Via InvestorPlace
    TEVA Stock Pops 4% as Teva Receives FDA Approval
    Via InvestorPlace
    Exposures Product Safety
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.